Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Luminescent nanosensors for ratiometric monitoring of three-dimensional oxygen gradients in lab and clinical Pseudomonas aeruginosa biofilms.

Jewell MP, Galyean AA, Harris JK, Zemanick ET, Cash KJ.

Appl Environ Microbiol. 2019 Aug 16. pii: AEM.01116-19. doi: 10.1128/AEM.01116-19. [Epub ahead of print]

PMID:
31420335
2.

Prevention of chronic infection with Pseudomonas aeruginosa infection in cystic fibrosis.

Zemanick ET, Bell SC.

Curr Opin Pulm Med. 2019 Aug 7. doi: 10.1097/MCP.0000000000000616. [Epub ahead of print]

PMID:
31397692
3.

Dissociation of systemic and mucosal autoimmunity in cystic fibrosis.

Theprungsirikul J, Skopelja-Gardner S, Meagher RE, Clancy JP, Zemanick ET, Ashare A, Rigby WFC.

J Cyst Fibros. 2019 Jun 28. pii: S1569-1993(19)30807-0. doi: 10.1016/j.jcf.2019.06.006. [Epub ahead of print]

PMID:
31262645
4.

Highlights from the 2018 North American cystic fibrosis conference.

Martiniano SL, Daines CL, Dellon EP, Esther CR Jr, Muhlebach MS, Ong T, Rabinowitz EC, Toprak D, Zemanick ET.

Pediatr Pulmonol. 2019 Jul;54(7):941-948. doi: 10.1002/ppul.24356. Epub 2019 May 15. Review.

PMID:
31091021
5.

Unraveling the CFTR Function-Phenotype Connection for Precision Treatment in Cystic Fibrosis.

Zemanick ET, Polineni D.

Am J Respir Crit Care Med. 2019 May 1;199(9):1053-1054. doi: 10.1164/rccm.201903-0696ED. No abstract available.

6.

Changes in microbiome diversity following beta-lactam antibiotic treatment are associated with therapeutic versus subtherapeutic antibiotic exposure in cystic fibrosis.

Hahn A, Fanous H, Jensen C, Chaney H, Sami I, Perez GF, Koumbourlis AC, Louie S, Bost JE, van den Anker JN, Freishtat RJ, Zemanick ET, Crandall KA.

Sci Rep. 2019 Feb 22;9(1):2534. doi: 10.1038/s41598-019-38984-y.

7.

Application of multiple event analysis as an alternative approach to studying pulmonary exacerbations as an outcome measure.

Juarez-Colunga E, Rosenfeld M, Zemanick ET, Wagner B.

J Cyst Fibros. 2019 Jan 11. pii: S1569-1993(18)30943-3. doi: 10.1016/j.jcf.2018.12.005. [Epub ahead of print]

PMID:
30642785
8.

Novel Application of Aptamer Proteomic Analysis in Cystic Fibrosis Bronchoalveolar Lavage Fluid.

DeBoer EM, Wagner BD, Popler J, Harris JK, Zemanick ET, Accurso FJ, Sagel SD, Deterding RR.

Proteomics Clin Appl. 2019 May;13(3):e1800085. doi: 10.1002/prca.201800085. Epub 2019 Jan 3.

PMID:
30431231
9.

Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis.

Hoppe JE, Wagner BD, Accurso FJ, Zemanick ET, Sagel SD.

J Cyst Fibros. 2018 Nov;17(6):760-768. doi: 10.1016/j.jcf.2018.05.015. Epub 2018 Jun 18.

PMID:
29921503
10.

On the Use of Diversity Measures in Longitudinal Sequencing Studies of Microbial Communities.

Wagner BD, Grunwald GK, Zerbe GO, Mikulich-Gilbertson SK, Robertson CE, Zemanick ET, Harris JK.

Front Microbiol. 2018 May 22;9:1037. doi: 10.3389/fmicb.2018.01037. eCollection 2018.

11.

Highlights from the 2017 North American Cystic Fibrosis Conference.

Martiniano SL, Toprak D, Ong T, Zemanick ET, Daines CL, Muhlebach MS, Esther CR Jr, Dellon EP.

Pediatr Pulmonol. 2018 Jul;53(7):979-986. doi: 10.1002/ppul.24000. Epub 2018 Apr 16. Review.

PMID:
29660839
12.

Volatile molecules from bronchoalveolar lavage fluid can 'rule-in' Pseudomonas aeruginosa and 'rule-out' Staphylococcus aureus infections in cystic fibrosis patients.

Nasir M, Bean HD, Smolinska A, Rees CA, Zemanick ET, Hill JE.

Sci Rep. 2018 Jan 16;8(1):826. doi: 10.1038/s41598-017-18491-8.

13.

Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis.

Hoppe JE, Wagner BD, Sagel SD, Accurso FJ, Zemanick ET.

BMC Pulm Med. 2017 Dec 11;17(1):188. doi: 10.1186/s12890-017-0546-8.

14.

Airway microbiota across age and disease spectrum in cystic fibrosis.

Zemanick ET, Wagner BD, Robertson CE, Ahrens RC, Chmiel JF, Clancy JP, Gibson RL, Harris WT, Kurland G, Laguna TA, McColley SA, McCoy K, Retsch-Bogart G, Sobush KT, Zeitlin PL, Stevens MJ, Accurso FJ, Sagel SD, Harris JK.

Eur Respir J. 2017 Nov 16;50(5). pii: 1700832. doi: 10.1183/13993003.00832-2017. Print 2017 Nov.

15.

Highlights from the 2016 North American Cystic Fibrosis Conference.

Zemanick ET, Daines CL, Dellon EP, Esther CR Jr, Kinghorn B, Ong T, Muhlebach MS.

Pediatr Pulmonol. 2017 Aug;52(8):1103-1110. doi: 10.1002/ppul.23707. Epub 2017 Jul 11. Review.

16.

Impact of enzymatic digestion on bacterial community composition in CF airway samples.

Williamson KM, Wagner BD, Robertson CE, Johnson EJ, Zemanick ET, Harris JK.

PeerJ. 2017 May 30;5:e3362. doi: 10.7717/peerj.3362. eCollection 2017.

17.

Lessons from the lower airway microbiome in early CF.

Hoppe JE, Zemanick ET.

Thorax. 2017 Dec;72(12):1063-1064. doi: 10.1136/thoraxjnl-2017-210060. Epub 2017 Apr 27. No abstract available.

PMID:
28450530
18.

Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR.

Donaldson SH, Solomon GM, Zeitlin PL, Flume PA, Casey A, McCoy K, Zemanick ET, Mandagere A, Troha JM, Shoemaker SA, Chmiel JF, Taylor-Cousar JL.

J Cyst Fibros. 2017 May;16(3):371-379. doi: 10.1016/j.jcf.2017.01.009. Epub 2017 Feb 13.

19.

Airway Microbiota in Bronchoalveolar Lavage Fluid from Clinically Well Infants with Cystic Fibrosis.

Laguna TA, Wagner BD, Williams CB, Stevens MJ, Robertson CE, Welchlin CW, Moen CE, Zemanick ET, Harris JK.

PLoS One. 2016 Dec 8;11(12):e0167649. doi: 10.1371/journal.pone.0167649. eCollection 2016.

20.

Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial.

Muhlebach MS, Beckett V, Popowitch E, Miller MB, Baines A, Mayer-Hamblett N, Zemanick ET, Hoover WC, VanDalfsen JM, Campbell P, Goss CH; STAR-too study team.

Thorax. 2017 Apr;72(4):318-326. doi: 10.1136/thoraxjnl-2016-208949. Epub 2016 Nov 15.

21.

Cystic Fibrosis: Microbiology and Host Response.

Zemanick ET, Hoffman LR.

Pediatr Clin North Am. 2016 Aug;63(4):617-36. doi: 10.1016/j.pcl.2016.04.003. Review.

22.

Highlights from the 2015 North American Cystic Fibrosis Conference.

Zemanick ET, Ong T, Daines CL, Dellon EP, Muhlebach MS, Esther CR Jr.

Pediatr Pulmonol. 2016 Jun;51(6):650-7. doi: 10.1002/ppul.23441. Epub 2016 Apr 13.

23.

Cystic fibrosis: a model system for precision medicine.

Martiniano SL, Sagel SD, Zemanick ET.

Curr Opin Pediatr. 2016 Jun;28(3):312-7. doi: 10.1097/MOP.0000000000000351. Review.

24.

Clinical Practice Guidelines From the Cystic Fibrosis Foundation for Preschoolers With Cystic Fibrosis.

Lahiri T, Hempstead SE, Brady C, Cannon CL, Clark K, Condren ME, Guill MF, Guillerman RP, Leone CG, Maguiness K, Monchil L, Powers SW, Rosenfeld M, Schwarzenberg SJ, Tompkins CL, Zemanick ET, Davis SD.

Pediatrics. 2016 Apr;137(4). pii: e20151784. doi: 10.1542/peds.2015-1784. Epub 2016 Mar 23. Review.

25.

Alterations of the Nasopharyngeal Microbiota in Infants with Cystic Fibrosis. Cystic Fibrosis Transmembrane Conductance Regulator and Antibiotic Effects.

Zemanick ET, Wainwright C.

Am J Respir Crit Care Med. 2016 Mar 1;193(5):473-4. doi: 10.1164/rccm.201511-2200ED. No abstract available.

PMID:
26930426
26.

Molecular Identification of Staphylococcus aureus in Airway Samples from Children with Cystic Fibrosis.

Johnson EJ, Zemanick ET, Accurso FJ, Wagner BD, Robertson CE, Harris JK.

PLoS One. 2016 Jan 25;11(1):e0147643. doi: 10.1371/journal.pone.0147643. eCollection 2016.

27.

Editorial Commentary: Pseudomonas aeruginosa Eradication: How Do We Measure Success?

Zemanick ET, Laguna TA.

Clin Infect Dis. 2015 Sep 1;61(5):716-8. doi: 10.1093/cid/civ379. Epub 2015 May 13. No abstract available.

28.

Cholesteryl esters are elevated in the lipid fraction of bronchoalveolar lavage fluid collected from pediatric cystic fibrosis patients.

Ma DC, Yoon AJ, Faull KF, Desharnais R, Zemanick ET, Porter E.

PLoS One. 2015 Apr 28;10(4):e0125326. doi: 10.1371/journal.pone.0125326. eCollection 2015.

29.

Sputum induction improves detection of pathogens in children with cystic fibrosis.

Hoppe JE, Towler E, Wagner BD, Accurso FJ, Sagel SD, Zemanick ET.

Pediatr Pulmonol. 2015 Jul;50(7):638-46. doi: 10.1002/ppul.23150. Epub 2015 Jan 7.

30.

Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods.

Zemanick ET, Wagner BD, Robertson CE, Stevens MJ, Szefler SJ, Accurso FJ, Sagel SD, Harris JK.

Ann Am Thorac Soc. 2015 Feb;12(2):221-9. doi: 10.1513/AnnalsATS.201407-310OC.

31.

Narrowing in on early cystic fibrosis lung disease.

Zemanick ET, Hoffman L, Rosenfeld M.

Am J Respir Crit Care Med. 2014 Nov 15;190(10):1082-4. doi: 10.1164/rccm.201410-1929ED. No abstract available.

PMID:
25398104
32.

Advances in the diagnosis and treatment of cystic fibrosis.

Martiniano SL, Hoppe JE, Sagel SD, Zemanick ET.

Adv Pediatr. 2014 Aug;61(1):225-43. doi: 10.1016/j.yapd.2014.03.002. Epub 2014 May 3. Review.

PMID:
25037130
33.

Cystic fibrosis transmembrane conductance regulator and pseudomonas.

Zemanick ET, Accurso FJ.

Am J Respir Crit Care Med. 2014 Apr 1;189(7):763-5. doi: 10.1164/rccm.201402-0209ED. No abstract available.

34.

Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis.

Zemanick ET, Emerson J, Thompson V, McNamara S, Morgan W, Gibson RL, Rosenfeld M; EPIC Study Group.

Pediatr Pulmonol. 2015 Jan;50(1):42-8. doi: 10.1002/ppul.23036. Epub 2014 Mar 18.

PMID:
24644274
35.

Microbes in bronchiectasis: the forest or the trees?

Harris JK, Zemanick ET.

Am J Respir Crit Care Med. 2013 May 15;187(10):1044-5. doi: 10.1164/rccm.201302-0240ED. No abstract available.

PMID:
23675713
36.

Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations.

Zemanick ET, Harris JK, Wagner BD, Robertson CE, Sagel SD, Stevens MJ, Accurso FJ, Laguna TA.

PLoS One. 2013 Apr 30;8(4):e62917. doi: 10.1371/journal.pone.0062917. Print 2013.

37.

Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis.

Sagel SD, Wagner BD, Anthony MM, Emmett P, Zemanick ET.

Am J Respir Crit Care Med. 2012 Nov 1;186(9):857-65. doi: 10.1164/rccm.201203-0507OC. Epub 2012 Aug 16.

38.

Newborn screening for cystic fibrosis.

Wagener JS, Zemanick ET, Sontag MK.

Curr Opin Pediatr. 2012 Jun;24(3):329-35. doi: 10.1097/MOP.0b013e328353489a. Review.

PMID:
22491493
39.

The airway microbiome in cystic fibrosis and implications for treatment.

Zemanick ET, Sagel SD, Harris JK.

Curr Opin Pediatr. 2011 Jun;23(3):319-24. doi: 10.1097/MOP.0b013e32834604f2. Review.

PMID:
21494150
40.

Reliability of quantitative real-time PCR for bacterial detection in cystic fibrosis airway specimens.

Zemanick ET, Wagner BD, Sagel SD, Stevens MJ, Accurso FJ, Harris JK.

PLoS One. 2010 Nov 30;5(11):e15101. doi: 10.1371/journal.pone.0015101.

41.

Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures.

Zemanick ET, Wagner BD, Harris JK, Wagener JS, Accurso FJ, Sagel SD.

Pediatr Pulmonol. 2010 Jun;45(6):569-77. doi: 10.1002/ppul.21221.

42.

Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.

Zemanick ET, Harris JK, Conway S, Konstan MW, Marshall B, Quittner AL, Retsch-Bogart G, Saiman L, Accurso FJ.

J Cyst Fibros. 2010 Jan;9(1):1-16. doi: 10.1016/j.jcf.2009.09.003. Epub 2009 Oct 14. Review.

43.

Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis.

Harris JK, De Groote MA, Sagel SD, Zemanick ET, Kapsner R, Penvari C, Kaess H, Deterding RR, Accurso FJ, Pace NR.

Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20529-33. Epub 2007 Dec 11.

Supplemental Content

Loading ...
Support Center